Ricardo Defense awarded a sole-source contract valued at over $89M to deliver 9,480 ABS/ESC retrofit kits to US Army
17.3.2021 10:00:00 EET | Business Wire | Press release
The Army today awarded Ricardo Defense a base contract to provide up to 9,480 critical safety improvement Antilock Brake System / Electronic Stability Control (ABS/ESC) retrofit kits over the next three years for the U.S. Army’s High Mobility Multipurpose Wheeled Vehicle (HMMWV). The first delivery order, under the three-year base contract, will include $10M to deliver 1,200 ABS/ESC retrofit kits by August 2021. A second delivery order is expected later this year to increase deliveries to approximately 2,000 ABS/ESC retrofit kits over the next 12 months.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210317005179/en/
High Mobility Multipurpose Wheeled Vehicle (HMMWV) (Photo: Business Wire)
Historical data presented by the National Highway Traffic Safety Administration (NHTSA) indicates that the application of ABS and ESC reduces the number of fatal rollovers by 74%, and fatal impacts by 45%. Today’s initial award marks the beginning of a multi-year contract for Ricardo Defense to improve the safety and operational readiness of the fielded HMMWV fleet for U.S. soldiers and HMMWV operators worldwide.
Chet Gryczan, president of Ricardo Defense said: “This is a significant milestone and strong example of Ricardo Defense’s commitment to provide solutions to meet the tough challenges facing our customers and ensure the safety of our men and women in uniform. In fielding this system, we are tremendously proud to contribute to the Army’s commitment to the safety of our soldiers and civilians alike.”
The HMMWV is projected to remain in the U.S. Army’s fleet until 2050. In 2018, the Army mandated that all new HMMWVs coming off the new vehicle production line must have the ABS/ESC system installed. Since July 2018, more than 5,000 new production or Recapitalized HMMWV vehicles have been delivered to the US Army with Ricardo’s ABS/ESC technology. In 2019, the Army provisioned Ricardo’s ABS/ESC retrofit kit into the national stock system for retrofit of vehicles not addressed during new production or Recapitalization. This dual-approach ensures that all HMMWVs in the enduring fleet are eventually fit with the ABS/ESC rollover mitigation technology.
A spokesperson for the U.S. Army, Product Director Light Tactical Vehicles said, “The ABS/ESC retrofit contract award is a culmination of a lot of great work from all parties, and is an essential step in providing this critical safety solution to our fielded HMMWV fleet. We are extremely proud of the Army’s collaboration with Ricardo Defense to provide an affordable and attainable solution that significantly reduces loss of control incidents, vehicle rollover incidents, and ultimately helps save lives.”
Red River Army Depot, in partnership with Ricardo Defense, will complete ABS/ESC retrofit installations at the Army’s Center of Industrial and Technical Excellence for tactical wheeled vehicles in Texarkana, Texas and at regional sites across the U.S. beginning in March 2021.
ENDS
About Ricardo
Ricardo plc is a world-class environmental, engineering and strategic consulting company listed on the London Stock Exchange. With over 100 years of engineering excellence, we provide exceptional levels of expertise in delivering leading edge and innovative cross sector sustainable products and solutions, helping our global customers increase efficiencies, achieve growth and create a clear and safer future. Our mission is clear –- to create a world fit for the future. For more information visit www.ricardo.com
About Ricardo Defense, Inc
Ricardo Defense Inc. is a Ricardo subsidiary delivering high-value system engineering, mission critical software, vehicle builds, and safety-critical products to the US Department of Defense as well as governments and defense industry suppliers world-wide. Ricardo Defense is a recognized leader in the integration of complex systems and acquisition planning and system support services for major defense programs around the globe.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210317005179/en/
Contact information
For Ricardo:
Kate Caulfield
Ricardo Defense
Email: kathryn.caulfield@ricardodefense.com
Telephone: (586) 899-7668
Ricardo Media Office
Gill Gibbons
Email: media@ricardo.com
Telephone: +44 (0) 7795 342804
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 20263.10.2026 17:50:00 EEST | Press release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of its 400+ patient Phase 1b C-800-01 trial. The study evaluated botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), Agenus’ anti-PD-1 antibody. The results, including three-year survival and outcomes by sensitivity to platinum-based chemotherapy and by prior treatment, were presented at the 2026 International Gynecologic Cancer Society (IGCS) Annual Global Meeting in Montréal, Canada. Among patients evaluable for efficacy, three-year overall survival was 48% (n=35), unchanged from the two-year estimate, suggesting durable clinical benefit in this population. Responses and long-term survival were observed in both platinum-sensitive and platinum-resistant or refractory disease. At the last follow-up, 25% of patients who received at least one dose of treatment (11 of 44) were alive
emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer2.10.2026 18:12:00 EEST | Press release
emnify, a global leader in IoT connectivity, today announced the appointments of Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001902751/en/ emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer The appointments follow the recent naming of Kenneth De Spiegeleire as Chief Executive Officer and Frank Stoecker as Executive Chairman of the Board. Together, these leadership changes strengthen emnify financial, operational, and commercial capabilities as the company enters its next phase of international growth. “We have proven momentum. Our ambition is to now turn it into global category leadership,” said Kenneth De Spiegeleire, CEO of emnify. “That requires sharper focus, disciplined execution, and the right capabilities in the right seats. Sacha brings financial lead
Tacton Appoints Former IFS Executive Merlin Knott as Chief Commercial Officer to Accelerate Global Growth and Scale Beyond CPQ2.10.2026 16:00:00 EEST | Press release
Tacton, a global leader in Configure, Price, Quote (CPQ) software and configuration solutions for manufacturers of complex products, today announced the appointment of Merlin Knott as Chief Commercial Officer (CCO). In this role, Knott will lead Tacton’s global commercial organization, including marketing, sales, and pre-sales, aligning the teams responsible for bringing Tacton’s solutions to market, and driving value to its customers and partners globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261002794882/en/ Merlin Knott, Chief Commercial Officer, Tacton Knott joins Tacton with decades of experience building and scaling commercial organizations across the enterprise software industry. Most recently, he held senior leadership roles at IFS, the world’s leading provider of Industrial AI software, where he led global partner and channel operations before becoming President of the company’s Enterprise Service Manageme
EDW Presents 2026 Data Quality Award to Repeat Winner Domivest2.10.2026 16:00:00 EEST | Press release
European DataWarehouse (EDW) presented its fifth annual Data Quality Award at the 2026 TSI Congress in Berlin. This year, EDW's Best Data Quality – Deal of the Year (2026) award was presented to Domivest B.V. for its transaction Domi 2023-1 B.V., recognising the firm's outstanding commitment to accurate, complete, and consistent reporting. The award is based on EDW's proprietary data quality scoring methodology, which evaluates transactions against thousands of validation rules and checks. Data quality excellence is not a one-off achievement. The fact that the same issuers continue to rank among the top performers year after year demonstrates that superior data quality is the result of sustained commitment, robust processes, and ongoing investment. "Receiving the Data Quality Award for a second time means a great deal to us. Transparent, accurate loan-level data is key to investor trust in our transactions, and we are grateful to European DataWarehouse for recognising the work our trea
ILiAD Biotechnologies Expands BPZE1 Public Health and Commercial Potential with Publication of Pediatric Phase 2b Study in The Lancet Infectious Diseases2.10.2026 15:00:00 EEST | Press release
ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the publication of results from its Phase 2b SUPER (Stand Up to Pertussis) clinical trial in The Lancet Infectious Diseases. This randomized, double blind, placebo- and active-comparator-controlled trial demonstrated that BPZE1, a live attenuated intranasal pertussis vaccine, induced robust nasal mucosal immune responses in healthy children aged 6 through 17 years (LINK). The study demonstrated that a single intranasal dose of BPZE1 induced nasal mucosal immune responses against all Bordetella pertussis antigens tested and was well tolerated, both when administered alone and when co-administered with a tetanus-diphtheria-acellular pertussis (Tdap) booster vaccine. The multi-center Phase 2b trial enrolled 366 participants across 16 sites in the United Kingdom, Australia, and Costa Rica and included participants
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
